N. Frede

发表

Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2

C. Klemann, Nadezhda Camacho-Ordóñez, Linlin Yang, 2019, Front. Immunol..

Phenotype, penetrance, and treatment of 133 cytotoxic T‐lymphocyte antigen 4–insufficient subjects

O. Elemento, T. Giese, A. Schulz, 2018, The Journal of allergy and clinical immunology.

Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease

N. Frede, B. Grimbacher, W. Kreisel, 2014, BMC Immunology.

Screening of 181 Patients With Antibody Deficiency for Deficiency of Adenosine Deaminase 2 Sheds New Light on the Disease in Adulthood

V. Lougaris, N. Frede, K. Warnatz, 2017, Arthritis & rheumatology.

Targeted Gene Panel Sequencing for Early-onset Inflammatory Bowel Disease and Chronic Diarrhea

C. Klein, A. Franke, H. von Bernuth, 2017, Inflammatory bowel diseases.

Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.

R. Voll, N. Frede, U. Salzer, 2017, The journal of allergy and clinical immunology. In practice.

NFKB1 regulates human NK cell maturation and effector functions.

V. Lougaris, A. Plebani, G. Tabellini, 2017, Clinical immunology.

Gut Involvement in Cellular Immunodeficiencies

M. D’Elios, N. Frede, C. Della Bella, 2021 .

Characterization of the clinical and immunological phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations.

William J. Astle, Sri V. V. Deevi, Kenneth G. C. Smith, 2020, The Journal of allergy and clinical immunology.

Autoantibodies against BAFF, APRIL or IL21 - an alternative pathogenesis for antibody-deficiencies?

L. Hammarström, N. Frede, B. Grimbacher, 2017, BMC Immunology.

Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells.

C. Smulski, R. Voll, N. Frede, 2019, Journal of autoimmunity.

Respiratory tract infections and risk factors for infection in a cohort of 330 patients with axial spondyloarthritis or psoriatic arthritis

R. Voll, N. Frede, A. Nieters, 2022, Frontiers in Immunology.

The TH1 phenotype of follicular helper T cells indicates an IFN‐&ggr;–associated immune dysregulation in patients with CD21low common variable immunodeficiency

M. van der Burg, N. Frede, A. Bulashevska, 2017, The Journal of allergy and clinical immunology.

Successful Granulocyte Colony-stimulating Factor Treatment of Relapsing Candida albicans Meningoencephalitis Caused by CARD9 Deficiency.

N. Frede, B. Grimbacher, N. Oztoprak, 2016, The Pediatric infectious disease journal.

The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1

J. Franco, T. Torgerson, R. Russell, 2015, Journal of Clinical Immunology.

Explorer The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT 1

J. Franco, T. Torgerson, R. Russell, 2015 .

A biallelic mutation in IL6ST encoding the GP130 co-receptor causes immunodeficiency and craniosynostosis

S. Holland, D. Schmidt-Arras, S. Twigg, 2017, The Journal of experimental medicine.

Haploinsufficiency of the NF-κB1 Subunit p50 in Common Variable Immunodeficiency.

A. Schäffer, H. Cao, P. Browett, 2015, American journal of human genetics.

Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation.

B. Hartmann, C. Klein, J. Puck, 2013, The Journal of allergy and clinical immunology.

Infant colitis—it's in the genes

N. Sebire, N. Frede, B. Grimbacher, 2010, The Lancet.

The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1

J. Franco, T. Torgerson, R. Russell, 2014, Journal of Clinical Immunology.

Non permissive bone marrow environment impairs early B-cell development in common variable immunodeficiency.

M. Erlacher, R. Voll, N. Frede, 2020, Blood.

Autosomal-dominant immune dysregulation syndrome in humans with CTLA4 mutations

A. Schäffer, R. Backofen, S. Ehl, 2014, Nature Medicine.

The expansion of human T-bethighCD21low B cells is T cell dependent

J. Casanova, M. Boerries, M. van der Burg, 2021, Science Immunology.

Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis.

M. Mehling, C. Hess, P. Hruz, 2017, The Journal of allergy and clinical immunology.

Genetic Analysis of a Cohort of 275 Patients with Hyper-IgE Syndromes and/or Chronic Mucocutaneous Candidiasis

P. Soler-Palacín, V. Wahn, H. von Bernuth, 2021, Journal of Clinical Immunology.

Genetics of Cellular Immunodeficiencies

N. Frede, 2021 .

JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis

R. Voll, N. Frede, M. Rizzi, 2023, Frontiers in Immunology.

Autoantibodies against BAFF, APRIL or IL21 - an alternative pathogenesis for antibody-deficiencies?

L. Hammarström, N. Frede, B. Grimbacher, 2017, BMC Immunology.

Sleep behaviour differs in women and men with psoriatic arthritis and axial spondyloarthritis with impact on quality of life and depressive symptoms

N. Frede, S. Finzel, J. Thiel, 2023, RMD Open.

Autosomal-dominant immune dysregulation syndrome in humans with CTLA4 mutations

A. Schäffer, R. Backofen, S. Ehl, 2014, Nature Medicine.

Psoriasis and Psoriatic Arthritis Have a Major Impact on Quality of Life and Depressive Symptoms: A Cross-Sectional Study of 300 Patients

N. Frede, L. Tebartz van Elst, D. Endres, 2023, Rheumatology and Therapy.

Burden of disease and impact on quality of life in chronic back pain – a comparative cross-sectional study of 150 axial spondyloarthritis and 150 orthopedic back pain patients

N. Frede, S. Finzel, D. Endres, 2023, Frontiers in medicine.

Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.

R. Voll, N. Frede, U. Salzer, 2017, The journal of allergy and clinical immunology. In practice.